Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

Stock Information for Vistagen Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vistagen Therapeutics Inc.

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.